Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Prostate Cancer Metastatic 1Histiocytic Sarcoma 1

Interventions

enzalutamide 7Prednisone 7cabazitaxel 6Radiosurgery 6Docetaxel 5Androgen Antagonists 4Abiraterone Acetate 4XRP6258 2Standard of Care 2talazoparib 1sipuleucel-T 1rucaparib 1pembrolizumab 1olaparib 1gallium 68 PSMA-11 1fludrocortisone acetate 1darolutamide 1apalutamide 1Zuclomiphene 1Radiotherapy, Image-Guided 1Radiotherapy 1Prednisolone 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Midazolam 1Lutetium-177 1Lutetium 1Lenograstim 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer Metastatic × LY3023414 × Genitourinary × Clear all
NCT02407054 2021-05-11

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Eli Lilly and Company

Phase 2 Completed
142 enrolled 16 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡